Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NLS Pharmaceutics ( (NLSP) ) has shared an update.
On August 21, 2025, NLS Pharmaceutics announced the rescheduling of its Extraordinary Shareholders’ Meeting to September 16, 2025, to allow more time for evaluating comments from the U.S. SEC regarding its pending merger with Kadimastem Ltd. This delay aims to ensure shareholders have the most complete information for decision-making, reflecting the company’s commitment to transparency and regulatory compliance.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a pharmaceutical company based in Zurich, Switzerland, focusing on the development of therapeutics for the treatment of central nervous system disorders.
Average Trading Volume: 259,628
Technical Sentiment Signal: Sell
Current Market Cap: $9.46M
Find detailed analytics on NLSP stock on TipRanks’ Stock Analysis page.